Dipeptidyl peptidase-4 (DPP-4) inhibitors are a newer class of oral hypoglycemic agents for the management of diabetes that elevate the plasma concentration of active glucagon-like peptide-1 via inhibition of DPP-4. They effectively lower not only glycosylated hemoglobin levels, but also fasting and postprandial plasma glucose levels. Patients with diabetes occasionally consume an overdose of oral hypoglycemic agents in suicide attempts: the prevalence of depression is high in patients with diabetes, and depression is a strong risk factor for suicide. We encountered an 86-year-old woman with type 2 diabetes and depression, who was transferred to the emergency room 4h after ingestion of 1,700 mg of the DPP-4 inhibitor sitagliptin (1,700 mg is 17 times greater than the approved maximum dose). Upon arrival, she was fully conscious, plasma glucose was 124 mg/dL, and serum immunoreactive insulin level was 5.81 μU/mL. Thereafter, the plasma concentration of sitagliptin rose to 3,793 nM, which is 4.5 times higher than the value found under regular treatment with the maximum dose. The patient did not suffer from hypoglycemia, suggesting that a single oral overdose of sitagliptin is unlikely to cause hypoglycemia. A literature review of oral anti-diabetic agents revealed that overdose of biguanides is occasionally fatal when immediate intensive care is not provided. In summary, sitagliptin is a good treatment option for diabetic elderly patients or patients with psychiatric disorders who are suicidal and do not require insulin.

Key words: Dipeptidyl peptidase-4 inhibitors, Hypoglycemia, Overdose, Sitagliptin

DIPEPTIDYL PEPTIDASE-4 (DPP-4) inhibitors have recently been approved worldwide for the management of diabetes. Although insulin is a well-known anti-diabetic agent that is occasionally used for attempting suicide, the effect of an oral overdose of anti-diabetic agents, such as sitagliptin, a DPP-4 inhibitor, remains unclear. The incidence of hypoglycemia across a range of sitagliptin doses (50, 100, and 200 mg) in a 12-week double-blind randomized controlled study in Japanese patients with type 2 diabetes mellitus was as low as 1.3-4.4% [1]. We present a case report of sitagliptin overdose in a suicide attempt. We also review the literature on overdose with oral anti-diabetic agents, and highlight the best use of oral anti-diabetic agents in elderly people and in patients with psychiatric disorders.

Case Report

An 86-year-old woman with a 10-year history of type 2 diabetes mellitus was admitted to our hospital after sitagliptin overdose (1,700 mg: 34 tablets, 50 mg each) in a suicide attempt. She had been suffering from depression, and was prescribed sitagliptin 50 mg/day for 10 months; her HbA1c levels were stable at about 7.9% (National Glycohemoglobin Standardization Program). On admission, she was conscious and alert. Her blood pressure was 124/80 mm Hg and body temperature was 36.5°C. Blood glucose and immunoreactive insulin levels were 124 mg/dL and 5.81 μU/mL, respectively. Other laboratory data were as follows: hemoglobin level, 12.3 g/dL; platelet count, 22.2 × 10^4/μL; aspartate transaminase level, 18 U/L; alanine transaminase, 11 U/L; creatinine level, 0.89 mg/dL; and HbA1c level, 8.2%.
The patient was treated with 500 mL of 4.3% glucose intravenously at a rate of 20 mL/min for the first 10 minutes. She was maintained on 1 L of intravenous 4.3% glucose for 10 hours until the following morning. As a total, we used 52 g glucose to prevent hypoglycemia. She did not suffer from hypoglycemia, and the next morning, she was allowed to have breakfast. She then resumed oral administration of 50 mg of sitagliptin at midday. After hospitalization, her blood glucose levels were monitored frequently (once every hour) for 10 hours, and they fluctuated between 130 and 200 mg/dL. Thereafter, preprandial and postprandial blood glucose levels were measured for 3 days, and hypoglycemia did not occur.

Serial plasma concentrations of sitagliptin were measured using protein precipitation and tandem mass spectrometry as reported elsewhere [2]. The levels of sitagliptin in the plasma the day before, 16 h after, and 7 days after the overdose were 197, 3,793, and 686 nM, respectively. The patient has since been followed up in an outpatient clinic without any adverse events being noted.

**Literature Review**

We conducted a MEDLINE review of the relevant medical literature on overdose with oral anti-diabetic agents, excluding co-injection of insulin, published from January 1960 to November 2011. We identified all reported cases and reviews using the following search terms: overdose, suicide, intentional, hypoglycemia, sulfonylureas (SU), biguanides, and diabetes.

Relevant publications were evaluated, and the information has been summarized in Tables 1 and 2. Although we found reports on SU, biguanides, and meglitinides, there were no reports on α-glucosidase inhibitors and thiazolidinediones.

### Sulfonylureas

There were 7 full articles describing SU overdose.

**Table 1** Clinical characteristics and outcome of previously reported sulfonylureas overdose

<table>
<thead>
<tr>
<th>First author [reference]</th>
<th>Number</th>
<th>Age (range)</th>
<th>Intentional overdose</th>
<th>Psychiatric disorders</th>
<th>Suicide attempt</th>
<th>Münchausen syndrome</th>
<th>Death</th>
<th>Accidental overdose</th>
<th>Death</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dougherty PP. [3]</td>
<td>13</td>
<td>49±29 (1-80)</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>N/A</td>
<td>N/A</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Glatstein M. [4]</td>
<td>10</td>
<td>8.6±6.6 (2-17)</td>
<td>4</td>
<td>N/A</td>
<td>4</td>
<td>N/A</td>
<td>0</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>McLaughlin SA. [5]</td>
<td>9</td>
<td>41±15 (19-63)</td>
<td>5</td>
<td>N/A</td>
<td>4</td>
<td>N/A</td>
<td>0</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Quadrani DA. [6]</td>
<td>93</td>
<td>3.5±2.0 (1-16)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>0</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Dewitt CR. [7]</td>
<td>76</td>
<td>60±24 (0-91)</td>
<td>6</td>
<td>N/A</td>
<td>N/A</td>
<td>3</td>
<td>N/A</td>
<td>11</td>
<td>N/A</td>
</tr>
<tr>
<td>Klonoff DC. [8]</td>
<td>69</td>
<td>35±14</td>
<td>26</td>
<td>9</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>43</td>
<td>N/A</td>
</tr>
<tr>
<td>Carr R. [9]</td>
<td>8</td>
<td>36±19 (5-46)</td>
<td>2</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>

**Table 2** Clinical characteristics and outcome of previously reported biguanides overdose

<table>
<thead>
<tr>
<th>First author [reference]</th>
<th>Number</th>
<th>Age (range)</th>
<th>Intentional overdose</th>
<th>Suicide attempt</th>
<th>MALA</th>
<th>Death</th>
<th>Accidental ingestion</th>
<th>MALA</th>
<th>Death</th>
</tr>
</thead>
<tbody>
<tr>
<td>Forrester MB. [10]</td>
<td>1528</td>
<td>50.5** (20-96)</td>
<td>439</td>
<td>420</td>
<td>N/A</td>
<td>N/A</td>
<td>1039</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Wills BK. [11]</td>
<td>412</td>
<td>N/A</td>
<td>219</td>
<td>N/A</td>
<td>13</td>
<td>N/A</td>
<td>190</td>
<td>1</td>
<td>N/A</td>
</tr>
<tr>
<td>von Mach MA. [12]</td>
<td>109</td>
<td>N/A</td>
<td>62</td>
<td>62</td>
<td>6</td>
<td>3</td>
<td>47</td>
<td>8</td>
<td>1</td>
</tr>
<tr>
<td>Peters N. [13]</td>
<td>160</td>
<td>66.8±13.6</td>
<td>5</td>
<td>5</td>
<td>3</td>
<td>0</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

*includes suspicious suicide attempt  **The age was available in 1316 patients.

MALA, metformin-associated lactic acidosis; N/A, not applicable
Overdose of a hypoglycemic agent

Overdose of a hypoglycemic agent

Discussion

Although the use of oral anti-diabetic agents differs slightly among countries according to their guidelines and treatment algorithms [15], any oral anti-diabetic agent may lead to death when ingested excessively. A review of overdose with oral anti-diabetic agents showed that biguanides are likely to be the most frequently encountered agent that may lead to death when intensive care is not provided promptly, although SU are not reported on as often as biguanides. There were no reports of any patient deaths from SU overdose as a suicide attempt. However, the age range for SU overdose is much larger than that for biguanides. The reports on SU include children who were given overdoses by their caregivers who had Münchausen syndrome by proxy: this was not the original target population of the literature review but this type of overdose is noteworthy.

Sitagliptin is a very strong inhibitor of DPP-4, as shown in a study of healthy subjects where single oral dose (sitagliptin 50 mg) and multiple oral doses (sitagliptin 50 mg/day × 10 days) resulted in 77.1% and 79.9% inhibitory potency, respectively. Interestingly, its inhibitory potency remained above 93% at a much higher dose of 800 mg [16]. These data suggest that the inhibitory potency of DPP-4 reaches a plateau despite elevated plasma sitagliptin levels. This partly explains there was no sudden decrease in blood glucose in the patient reported in our case study. It has also been reported that sustained exposure to glucagon-like peptide-1 at a high concentration can correct hyperglycemia, but does not cause hypoglycemia due to a glucose-dependent decline in plasma insulin levels [17]. Strong inhibition of DPP-4 has the potential to cause a sustained elevation of plasma incretin hormone levels. However, due to the glucose-dependent nature of the activity of incretins, this could also contribute to preventing hypoglycemia after sitagliptin overdose.

Pharmacokinetic parameters (T_{max} and C_{max}) after a single oral dose of sitagliptin (400 mg and 800 mg) in
healthy volunteers have been reported as follows: 1.5 h and 3640 nM, respectively, for 400 mg; and 1.0 h and 11,100 nM, respectively, for 800 mg [16]. This study showed that the immediate absorption of sitagliptin is followed by the rapid rise in plasma sitagliptin levels. The maximum plasma level of sitagliptin was 3,790 nM in the woman in our case report; she had ingested 1,700 mg of sitagliptin, which is equivalent to the $C_{\text{max}}$ in a healthy volunteer ingesting sitagliptin 400 mg for 10 consecutive days. In addition, Herman et al. reported that that single oral dose of 600 mg sitagliptin resulted in a $C_{\text{max}}$ of 7,000- 8,440 nM at 1.5-2 h after drug administration. However, the drug concentration declined to less than 1,000 nM at 16 h after ingestion in the healthy subjects [18]. Taken together with the fact that the patient in our case report had plasma sitagliptin levels of 3,793 nM at 16 h after drug ingestion, it is easy to speculate that the patient was exposed to a significantly higher plasma sitagliptin level for a longer time than has been described in any reports available so far. Even so, the patient showed neither symptomatic hypoglycemia nor any other adverse effects, suggesting that sitagliptin taken alone is a safe oral antihyperglycemic agent.

We could not completely exclude nocturnal hypoglycemia in our elderly patient who ingested 1,700 mg of sitagliptin. However, we did not observe evident hypoglycemia in this patient despite monitoring her blood glucose concentration carefully every few hours. This may be because: (1) blood glucose prior to the overdose of sitagliptin was poorly controlled; (2) it was a single oral overdose of sitagliptin; or (3) she did not take any other medications except sitagliptin. Nevertheless, we were able to find markedly elevated plasma sitagliptin levels even 16 h after drug ingestion. In conclusion, the present data suggest that a single overdose of sitagliptin is unlikely to cause fatal hypoglycemia and is thus one of the low-risk oral hypoglycemic agents. Sitagliptin should be considered for the treatment of diabetes in elderly people and in patients with psychiatric disorders who are suicidal.

References

Overdose of a hypoglycemic agent

the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:193-203.

